View This Email In Your Web Browser | Unsubscribe
|
Our New Pick is: IMSC
www.ImplantSciences.com
Current Price: $0.337
Members,
Let's start by saying that yesterday's pick was a disappointment.
The company gapped up heavily during the pre-market hours and when the trading session commenced, the stock's bid/ask spread was just far too big causing traders to quickly lose interest.
Even with the company moving as high of $0.105 per share for a +98.11% gain over our alert price, we simply can not label Thursday's pick as a winner.
The company's initial upward move was followed by a few profitable swings up and down the chart, however when all was said and done, it closed -16.67% in the red.
With that said, we've seen just 2 losers our of our last 18 picks.
In less than 2 months, those 16 winners have delivered as much as +1,267% in realistic gains!
Are you ready for profitable redemption? We are!
Immediately turn your attention to IMSC (Implant Sciences Corp.).
IMSC designs, manufactures, and sells explosives trace detection (ETD) and drugs trace detection solutions for multiple security applications including aviation, transportation, customs, air cargo, critical infrastructure protection, ports and borders, force protection, public safety, and emergency responders.
Founded in 1984, IMSC has a rich history of developing leading technologies in several markets, including medical products and semiconductor manufacturing. In 2008, the company restructured to a single business focus and is now a pure play in global Security, Safety, and Defense (SS&D) markets.
The company’s patented technology, used in its flagship products, the QS-H150 handheld explosives trace detector and the QS-B220 desktop explosives and drugs trace detector, is in use throughout the world.
IMSC successfully introduced its first handheld explosive trace detection product in 2003 and has sold more than thousands of ETD systems in more than 50 countries.
IMSC's ETD's have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint".
Homeland Security Research Corporation projects that the global ETD market will be approximately $1 billion by 2015.
Continuing ECAC Demand Leads to Follow-On Orders for European Nations as IMSC Ships Additional $1 Million of ETDs Worldwide
During early trading hours yesterday, IMSC announced that it has shipped approximately $1 million of its QS-B220 desktop explosives and drugs trace detectors and its QS-H150 handheld explosives trace detectors. A large portion of the sales, which were previously unannounced, were shipped to fulfill additional demand for aviation security in European nations. Over the past year, the company has been selected by high profile airports across 14 EU nations and has deployed over 1,000 units to support ECAC regulations.
"Implant Sciences continues to perform as the market leader, selected time and again by the busiest airports in Europe. We are pleased by our ongoing success in this market and we look forward to continuing to deliver to these customers as we work to develop new solutions and product offerings to meet their critical security needs," stated Dr. Darryl Jones, IMSC's Executive Vice President.
"The importance of having effective aviation security cannot be overstated. It is Implant Sciences' mission to support the safety of passengers as well as the employees of the airports, airlines, and retail stores within the airport," added Robert Liscouski, President of IMSC.
IMSC Extends Credit Agreements
Following the close of yesterday's session, IMSC announced the extension of its secured credit agreements with DMRJ Group, LLC ("DMRJ") and the group of investors represented by BAM Administrative Services, LLC ("BAM").
DMRJ and BAM have agreed to a time-limited extension of the maturity of all Implant Sciences' indebtedness under such secured credit agreements. IMSC has agreed to amend the terms of its Series H Convertible Preferred Stock, Series I Convertible Preferred Stock and Series J Convertible Preferred Stock, so that on any matter presented to the stockholders of the company, each holder of outstanding shares of each of the series of preferred stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of the preferred stock are convertible as of the record date for determining stockholders entitled to vote on such matter. The amended terms also dictate that such shares of preferred stock will, upon the sale of IMSC, be paid the amounts that they would have been paid if converted to common stock, without such shares being required to be converted. The parties also agreed to amend such series of preferred stock to remove the limitations on the holders thereof being able to convert such preferred stock to own more than 4.99% of IMSC's outstanding common stock. The company also agreed to revise the Series J Convertible Preferred Stock so that its holders are paid preferred payable in kind dividends of 15% per year. The remaining terms and conditions remain unchanged.
"We appreciate DMRJ and BAM's continued support, as the Board of Directors guides Implant Sciences toward a final decision point in the exploration of the strategic options for the business and to establish an improved capital structure," stated IMSC's CEO, Dr. Bill McGann. "Implant Sciences' success in the market has continued, and we remain on target in regards to our projected FY16 revenues. The updated agreement gives us the needed flexibility as we continue to execute on our ultimate goal of profitability."
IMSC Reports Second Quarter Fiscal 2016 Financial Results
On February 11, 2016, IMSC announced financial results for the three and six months ended December 31, 2015.
Revenues for the three months ended December 31, 2015 increased 380.7%, to $10.3 million, from $2.1 million for the comparable prior year period. The net loss for the three months ended December 31, 2015 was $3.3 million as compared with a net loss of $6.2 million for the comparable prior year period, a decrease of $2.9 million.
Revenues for the six months ended December 31, 2015 increased 515.6%, to $24.7 million, from $4.0 million for the comparable prior year period. The net loss for the six months ended December 31, 2015 was $4.2 million as compared with a net loss of $11.6 million for the comparable prior year period, a decrease of $7.4 million.
Earnings before interest, income taxes, depreciation and amortization, stock-based compensation, warrants issued to non-employees and common stock issued to consultants ("Adjusted EBITDA"), which is reconciled to net income in this press release, was a loss of $122,000 in the three months ended December 31, 2015, compared to a loss of $3,447,000 in the comparable prior year period and for the six months ended December 31, 2015, income of $2,017,000, compared to a loss of $5,843,000 in the comparable prior year period.
Dr. William McGann, CEO of IMSC, commented, "We are extremely pleased with the results of our recently completed quarter, a quarter in which we recorded revenues in excess of prior fiscal years revenues, a quarter in which we continued our penetration in the European aviation market with additional follow-on orders following the successful ECAC deployment in our first quarter and the initial delivery to U.S. airports under the delivery order with the Transportation Security Administration. The production ramp we experienced in our first quarter continued unabated this quarter, demonstrating our capabilities from not only a manufacturing and supply chain perspective, but from a working capital management perspective. In prior earnings releases and conference calls, we discussed our need to become self-sufficient and generate the cash flow required from internal operations. Thus far this year, we have successfully self-funded the significant working capital required to deliver the record revenues being reported today. We're continuing to invest and expect to increase our investment in technology, with the intent introduce new product that will increase the size of the security market we can penetrate."
Technical Analysis:
IMSC hit a new 52-week low of $0.245 per share on March 9, 2016.
The company has since moved higher, closing today's session up more than +11% at $0.337 per share following yesterday's huge sales news released during trading hours.
IMSC is still positioned just 9-cents above its 52-week low price.
The company also followed up by releasing another optimistic press release during afterhours that has yet been traded on...
With IMSC's 52-week high projecting upside of more than +150% from the current price, you're really not going to want to miss out on today's alert.
We are highly confident that IMSC is in the beginning stage of its biggest bull rally in history!
If you're looking to end the week on a high note, IMSC should be the only company on your radar today.
We ask that you act quick and get IMSC up on your trading screen right now!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
For more information on IMSC, please visit their website: www.ImplantSciences.com
Best regards,
The StockRockandRoll Team
|
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by MJ Capital, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “MJ Capital” refers to MJ Capital, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital owns no shares of any of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have NOT been compensated to conduct investor relations advertising and marketing for IMSC. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increas e in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in al l of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
|
|
|
|
|